

AMENDMENTS

1. (Currently amended) A compound comprising a modified oligonucleotide consisting of 8 to 80 linked nucleosides and having a nucleobase sequence complementary to the coding region or 3' UTR of SEQ ID NO: 3 and wherein said compound inhibits the expression of hydroxysteroid 11-beta dehydrogenase 1 ~~by at least 51%~~.

2. (Previously Presented) The compound of claim 1 comprising a single-stranded modified oligonucleotide.

3. (Canceled)

4. (Previously Presented) The compound of claim 2 wherein at least one internucleoside linkage is a modified internucleoside linkage.

5. (Original) The compound of claim 4 wherein the modified internucleoside linkage is a phosphorothioate linkage.

6. (Previously Presented) The compound of claim 2 wherein at least one nucleoside comprises a modified sugar moiety.

7. (Original) The compound of claim 6 wherein the modified sugar moiety is a 2'-O-methoxyethyl sugar moiety.

8. (Previously Presented) The compound of claim 2 wherein at least one nucleoside comprises a modified nucleobase.

9. (Original) The compound of claim 8 wherein the modified nucleobase is a 5-methylcytosine.

10. (Previously Presented) The compound of claim 2 wherein at least one nucleoside comprises a chimeric oligonucleotide.

11. (Currently amended) A compound 8 to 80 nucleobases in length which specifically hybridizes with at least an 8-nucleobase portion of an active site coding region or 3' UTR on a nucleic acid molecule encoding hydroxysteroid 11-beta dehydrogenase 1.

12. (Original) A composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier or diluent.

13. (Original) The composition of claim 12 further comprising a colloidal dispersion system.

14. (Previously Presented) The composition of claim 12 wherein the compound is an modified oligonucleotide.

15. (Withdrawn) A method of inhibiting the expression of hydroxysteroid 11-beta dehydrogenase 1 in cells or tissues comprising contacting said cells or tissues with the compound of claim 1 so that expression of hydroxysteroid 11-beta dehydrogenase 1 is inhibited.

16. (Withdrawn) A method of treating an animal having a disease or condition associated with hydroxysteroid 11-beta dehydrogenase 1 comprising administering to said animal a therapeutically or prophylactically effective amount of the compound of claim 1 so that expression of hydroxysteroid 11-beta dehydrogenase 1 is inhibited.

17. (Withdrawn) The method of claim 16 wherein the disease or condition is a metabolic disorder.

18. (Withdrawn) The method of claim 17 wherein the metabolic disorder is selected from the group consisting of obesity, diabetes, atherosclerosis and hyperlipidemia.

19. (Withdrawn) The method of claim 16 wherein the disease or condition is osteoporosis.

20. (Withdrawn) The method of claim 16 wherein the disease or condition is depression.

21. (Previously Presented) The compound of claim 6, wherein at least one modified sugar is a bicyclic sugar.

22. (Previously Presented) The compound of claim 2, wherein the modified oligonucleotide comprises:

a gap segment consisting of linked deoxynucleosides;

a 5' wing segment consisting of linked nucleosides;

a 3' wing segment consisting of linked nucleosides;

wherein the gap segment is positioned between the 5' wing segment and the 3' wing segment and wherein each nucleoside of each wing segment comprises a modified sugar.

23. (Previously Presented) The compound of claim 22, wherein the modified oligonucleotide comprises:

a gap segment consisting of ten linked deoxynucleosides;

a 5' wing segment consisting of five linked nucleosides;

a 3' wing segment consisting of five linked nucleosides;

wherein the gap segment is positioned between the 5' wing segment and the 3' wing segment, wherein each nucleoside of each wing segment comprises a 2'-O-methoxyethyl sugar; and wherein each internucleoside linkage is a phosphorothioate linkage.

24. (Previously Presented) The compound of claim 22, wherein the modified oligonucleotide consists of 20 linked nucleosides.